TCTR20210628005已完成3 期
Safety and immunogenicity of heterologous prime/boost inactivated COVID-19 vaccine and viral vector vaccine: an experimental clinical study
ational Research Council of Thailand (NRCT)0 个研究点目标入组 100 人开始时间: 2021年6月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Healthy individuals above 18 years of age
- •2. Have never been infected with SARS-CoV-2
- •3. Have never been vaccinated with COVID-19 vaccine
- •4. Not in the immunocompromised status
排除标准
- •1. Are being infected with COVID-19
- •2. Bleeding disorders
研究者
相似试验
已完成
2 期
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCOVID-19NCT04686773R-Pharm100
已完成
4 期
Safety and Immunological Responses after COVID-19 vaccination in Thai Pregnant WomePregnancy outcomes following COVID-19 pregnancy in Thai womenCOVID-19, vaccination, pregnant, ThaiTCTR20210717002ational Research Council of Thailand (NRCT)165
已完成
1 期
Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic AreasMalariaNCT01379430University of Oxford30
已完成
1 期
AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic AreaMalariaNCT01373879University of Oxford52
已完成
2 期
Safety and Immunogenicity of heterologous prime-boost SARS-CoV-2 vaccine with inactivated and mRNA vaccine platforms in healthy Thai adolescentPrevention of COVID-19 with heterologous prime-boost SARS-CoV-2 vaccine with inactivated and mRNA vaccine platforms, comparing standard dose vs low dose and 3-week vs 6-week interval, in healthy Thai adolescent.SARS-CoV-2, mRNA vaccine, Inactivated SARS-CoV-2 vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, ReactogenicityTCTR20210923012ational Vaccine Institute80